Dr. J. Francisco Nistal, from the “Marqués de Valdecilla” University Hospital, provides the clinical insight that brings this scientific discovery closer to its future application in patients
Researchers from CIBERCV, coordinated by the Severo Ochoa Molecular Biology Center (CBM-CSIC-UAM) and the Health Research Institute Fundación Jiménez Díaz (IIS-FJD), have identified a key mechanism involved in the development of aortic aneurysms and have demonstrated in animal models that it can be reversed through pharmacological treatments.
The discovery, published in the European Heart Journal, represents a decisive step toward less invasive therapies for a condition that until now has relied almost exclusively on surgery.
The study reveals that aortic aneurysms are characterized by an excessive accumulation of complex sugars in the arterial wall, caused by the abnormal activation of the so-called hexosamine biosynthetic pathway. This process progressively weakens vascular tissue and promotes vessel dilation. The researchers tested two experimental compounds that successfully reduced inflammation and strengthened the aortic wall in animal models, including mice with Marfan syndrome.
Additionally, they identified blood biomarkers that could enable early diagnosis, before the disease leads to severe complications.
Clinical participation and future outlook
The study not only demonstrates the feasibility of new therapeutic targets but also opens the possibility of early diagnosis. The authors identified blood biomarkers related to the activation of this metabolic pathway, which could allow the detection of the disease in its initial stages—before surgical intervention becomes necessary.
This research involved collaboration among several hospitals and leading research centers across Spain, including the “Marqués de Valdecilla” University Hospital, with the participation of Professor of Cardiovascular Surgery Dr. J. Francisco Nistal. His contribution helped bridge laboratory findings with clinical practice—an essential step toward translating these advances into patient care in the future.
Although further validation through clinical trials is still required, the study offers new opportunities for both the treatment and early detection of aortic aneurysms, a disease with a major public health impact. The possibility of preventing its progression through medication represents a tangible hope for reducing the mortality associated with this condition—paving the way for the development of less invasive and more effective therapies.
